Danaher's $9.9 Billion Deal to Acquire Masimo: A Strategic Move in Diagnostics
In a significant move in the life sciences industry, Danaher, a leading provider of tools and technologies for pharmaceutical companies, has announced its acquisition of Masimo, a renowned pulse oximeter manufacturer, for a staggering $9.9 billion. This deal marks Danaher's most substantial acquisition since its $5.7 billion purchase of Abcam in 2023, reflecting the company's strategic focus on expanding its diagnostics portfolio.
The acquisition, announced on Tuesday, offers Masimo shareholders $180 per share, representing a substantial 38.3% premium to the company's last closing price. This substantial offer highlights the confidence Danaher has in Masimo's value and its potential to enhance its diagnostics capabilities.
Life science firms have been navigating a complex landscape of uncertainty, including drug pricing regulations, potential tariff policies, and fluctuations in academic and government research funding. By acquiring Masimo, Danaher aims to diversify its offerings and strengthen its position in the patient monitoring market, particularly with the addition of non-invasive pulse oximeters to its existing invasive blood analyzer devices.
Masimo's recent legal victory against Apple, where a federal jury ordered Apple to pay $634 million for patent infringement, underscores the company's technological prowess and market presence. This acquisition also positions Danaher to leverage Masimo's expertise in blood-oxygen reading technology, further enhancing its diagnostic capabilities.
The deal is expected to close by the second half of 2026, with Danaher and Masimo anticipating positive financial impacts. Masimo's contribution is projected to boost Danaher's adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and a substantial $0.70 in the fifth full year post-acquisition. Despite the significant financial implications, the acquisition is expected to be accretive to Danaher's overall value.
Masimo's market capitalization of approximately $7 billion and Danaher's valuation of over $150 billion, according to Reuters, further emphasize the scale and potential of this strategic partnership. As Danaher integrates Masimo into its portfolio, the combined entity is poised to become a leading force in the diagnostics and patient monitoring sectors, offering innovative solutions that will shape the future of healthcare.
